Efficacy and safety of celecoxib in schizophrenia: a systematic review and meta-analysis of randomized controlled trials
Abstract
The hypothesis of immune and inflammatory dysregulation has been supported in the pathogenesis of schizophrenia; this systematic review and meta-analysis aims to evaluate the efficacy and safety of celecoxib, which is a COX-2 inhibitor with anti-inflammatory effects, in the management of schizophrenia. A comprehensive search of electronic databases, including PubMed, Scopus, Cochrane, and Web of Science, was performed in February 2025. We included only randomized controlled trials (RCTs) comparing celecoxib alone or as an adjunct to antipsychotics to placebo. Risk of bias was assessed using the ROB-2 tool, and the data of included studies were extracted and analyzed using RevMan 5.4 software. The primary outcome was the change in PANSS (Positive and Negative Syndrome Scale) total score. Seven RCT studies comprising 438 patients with schizophrenia were included in this study. The risk of bias was low in most of the included studies. Celecoxib showed statistically significant improvement in PANSS total score (MD = − 8.45, 95% CI [− 13.62, -3.28], p value = 0.001), PANSS-positive scale (MD = − 3.34, 95% CI [− 4.67, − 2.02], P < 0.00001), PANSS-negative sub-scales (MD = − 2.47, 95% CI [− 3.75, − 1.19], P = 0.00002), and general psychopathology (MD = − 4.47, 95% CI [8.10, − 0.85], P = 0.02). No publication bias was detected based on the DOI plot. This study’s findings provide insights into the potential anti-inflammatory benefits of celecoxib in schizophrenia treatment. However,…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 438 participants or records.
Read the paper
Related studies
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
- Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
- Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
- Celecoxib or naproxen treatment does not benefit depressive symptoms in persons aged 70 and over: findings from a randomized controlled trial
- Comparative Clinical Effectiveness of Nonsurgical Treatment Methods in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial
- Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.